Chartpoppers.com releases Investment overview on Pfizer Inc.
To find more information on Pfizer Inc. (NYSE:PFE) and other big board companies, Sign up to receive updates and Investment coverage from Chartpoppers.com
(CHARTPOPPERS.COM, April 16, 2010 ) Point Roberts, WA - Chartpoppers.com announces an investment report featuring company Pfizer Inc. (NYSE:PFE)
The Consolidated Investment Analysis on Pfizer Inc. (NYSE:PFE) will be in particular interest to other competing companys within in its sector, such as Bristol Myers Squibb Co. (NYSE:BMY), Merck & Co. Inc. (NYSE: MRK) and Johnson & Johnson. (NYSE: JNJ)
Pfizer Inc. is a research-based, global pharmaceutical company. The Company discovers, develops, manufactures and markets prescription medicines for humans and animals. It operates in two business segments: Pharmaceutical and Animal Health. Pfizer also operates several other businesses, including the manufacture of gelatin capsules, contract manufacturing and bulk pharmaceutical chemicals
Recent News on Pfizer Inc. (NYSE:PFE)
Pfizer Inc. said Thursday it will partner with reagent maker Stemgent Inc. to make new reagents available to researchers.
Reagents developed or discovered by Pfizer will be sold to researchers by Stemgent, the companies said. They said the reagents and other Stemgent products could help scientists working on stem cell and cell-based research in fields such as neuroscience, cancer, and metabolic diseases. The reagents are intended for use in non-human experiments.
To view the Consolidated Investment Analysis on Pfizer Inc. (NYSE:PFE) Please visit the stock pulse page at www.chartpoppers.com
In the report chartpoppers.com covers a recent Financial Summary, Analyst Consensus, Technical Analysis, Comparative Analysis and Insider Trading Activity.
The full report is available at www.chartpoppers.com
Chartpoppers.com is a market research and investment commentary provider. Chartpoppers.com aims to bring undervalued, up and coming companies into the sight of both experienced and non-experienced investors. We try to help investors, at whatever stage in their careers, to get a grasp on the necessary financial data that they need in order to make a educated investment decision. From our daily trading ideas to a in depth coverage of what’s going on in the markets, we are sure that chartpoppers.com is exactly what you need in order succeed.
For More information please visit us at www.chartpoppers.com
Chartpoppers.com Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. ChartPoppers.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
The Consolidated Investment Analysis on Pfizer Inc. (NYSE:PFE) will be in particular interest to other competing companys within in its sector, such as Bristol Myers Squibb Co. (NYSE:BMY), Merck & Co. Inc. (NYSE: MRK) and Johnson & Johnson. (NYSE: JNJ)
Pfizer Inc. is a research-based, global pharmaceutical company. The Company discovers, develops, manufactures and markets prescription medicines for humans and animals. It operates in two business segments: Pharmaceutical and Animal Health. Pfizer also operates several other businesses, including the manufacture of gelatin capsules, contract manufacturing and bulk pharmaceutical chemicals
Recent News on Pfizer Inc. (NYSE:PFE)
Pfizer Inc. said Thursday it will partner with reagent maker Stemgent Inc. to make new reagents available to researchers.
Reagents developed or discovered by Pfizer will be sold to researchers by Stemgent, the companies said. They said the reagents and other Stemgent products could help scientists working on stem cell and cell-based research in fields such as neuroscience, cancer, and metabolic diseases. The reagents are intended for use in non-human experiments.
To view the Consolidated Investment Analysis on Pfizer Inc. (NYSE:PFE) Please visit the stock pulse page at www.chartpoppers.com
In the report chartpoppers.com covers a recent Financial Summary, Analyst Consensus, Technical Analysis, Comparative Analysis and Insider Trading Activity.
The full report is available at www.chartpoppers.com
Chartpoppers.com is a market research and investment commentary provider. Chartpoppers.com aims to bring undervalued, up and coming companies into the sight of both experienced and non-experienced investors. We try to help investors, at whatever stage in their careers, to get a grasp on the necessary financial data that they need in order to make a educated investment decision. From our daily trading ideas to a in depth coverage of what’s going on in the markets, we are sure that chartpoppers.com is exactly what you need in order succeed.
For More information please visit us at www.chartpoppers.com
Chartpoppers.com Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. ChartPoppers.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Contact Information:
CHARTPOPPERS
Paul Marek
Tel: 6047245332
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
CHARTPOPPERS
Paul Marek
Tel: 6047245332
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
